TIGIT在泌尿系统肿瘤中的研究进展

打开文本图片集

Research progress of TIGIT in urinary system tumors

ABSTRACT：T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain （TIGIT） is a co-inhibitory receptor，which is highly expressed in a variety of malignant tumors.It can inhibit T cells and NK cells，and plays a key role in regulating immune response and tumor immune escape.TIGIT is closely related to the growth，metastasis and prognosis of urologic tumors，and its overexpression is associated with tumor progression and poor prognosis.Currently，TIGIT-based urologic tumors treatment strategies include monoclonal antibody therapy and combined immunotherapy，such as combination therapy with PD-1/PD-L1 and other drugs.Experimental and clinical studies on TIGIT are also being carried out and significant progress has been made.Therefore，TIGIT is expected to become a new target for immunotherapy and a biomarker for predicting the prognosis of patients with urologic tumors.This article reviews the research progress of TIGIT in urologic tumors.

KEY WORDS：T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain; kidney cancer; bladder cancer; prostate cancer; urogenital system tumor；programmed cell death protein-1

摘要：T细胞免疫球蛋白和酪氨酸抑制基序结构域蛋白（TIGIT）是一种共抑制性受体，在多种恶性肿瘤中高表达，能够对T细胞及自然杀伤（NK）细胞起到功能抑制作用，在调节免疫反应和肿瘤免疫逃逸中扮演着关键角色。（剩余12433字）